当前位置: 首页 >> 检索结果
共有 4060 条符合本次的查询结果, 用时 2.2916866 秒

3761. COUNTERPOINT: Should the New Definition of PH Be the Clinical Practice Standard? No.

作者: Robert P Frantz.
来源: Chest. 2020年157卷4期766-768页

3762. POINT: Should the New Definition of PH Be the Clinical Practice Standard? Yes.

作者: Bradley A Maron.
来源: Chest. 2020年157卷4期764-766页

3763. Selexipag Use in Clinical Practice: Mind the Gap.

作者: R James White.;Daniel J Lachant.
来源: Chest. 2020年157卷4期761-763页

3764. Point-of-Care Lung Ultrasound in Neonatology: Ready or Not, Here It Comes!

作者: Iuri Corsini.;Niccolò Parri.;Carlo Dani.
来源: Chest. 2020年157卷4期759-760页

3765. Lung Transplantation: Evolving Criteria for Referral and Patient Selection.

作者: Alicia B Mitchell.;Allan R Glanville.
来源: Chest. 2020年157卷4期757-758页

3766. Vitamin D Deficiency in COPD: Biomarker, Treatable Trait, or Just a Common Comorbidity?

作者: Stephen Milne.;Don D Sin.
来源: Chest. 2020年157卷4期755-756页

3767. Cardiovascular Risk in COPD: Searching for a Culprit.

作者: Isabelle Vivodtzev.;François Maltais.
来源: Chest. 2020年157卷4期753-754页

3768. In the Name of Contrast-Induced Acute Kidney Injury….

作者: Karim Lakhal.;Vincent Robert-Edan.;Stephan Ehrmann.
来源: Chest. 2020年157卷4期751-752页

3769. Repurposing the COPD Assessment Test: Another Step Forward for Bronchiectasis.

作者: Pamela J McShane.;Timothy R Aksamit.
来源: Chest. 2020年157卷4期749-750页

3770. Response.

作者: Shahrokh Javaheri.;Francisco Campos-Rodriguez.;Miguel Angel Martinez-Garcia.
来源: Chest. 2020年157卷4期1047-1048页

3771. CPAP Treatment and Cardiovascular Prevention: An Alternate Study Design That Includes Excessively Sleepy Patients.

作者: Bhajan Singh.;Greg Maislin.;Brendan T Keenan.;Nigel McArdle.;Diego R Mazzotti.;Ulysses Magalang.;Allan I Pack.; .
来源: Chest. 2020年157卷4期1046-1047页

3772. Observational Data With Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist May Not Reflect Current Practice With Single Triple Inhalers.

作者: Brian Lipworth.;Rory Chan.;Chris RuiWen Kuo.
来源: Chest. 2020年157卷4期1045页

3773. Response.

作者: Samy Suissa.;Pierre Ernst.
来源: Chest. 2020年157卷4期1045-1046页

3774. Response.

作者: Vishal J Tolia.;Danielle N O'Hara.;Kazi I Ullah.;Sahar Ahmad.
来源: Chest. 2020年157卷4期1044-1045页

3775. Shifting Gas Sign: Making the Diagnosis of Pneumoperitoneum More Secure.

作者: Li-Ta Keng.
来源: Chest. 2020年157卷4期1043-1044页

3776. Undiagnosed OSA May Significantly Affect Outcomes in Adults Admitted for COPD in an Inner-City Hospital.

作者: Mario Naranjo.;Leslee Willes.;Barbara A Prillaman.;Stuart F Quan.;Sunil Sharma.
来源: Chest. 2020年158卷3期1198-1207页
COPD is the second most common cause of hospital admission in the United States. OSA is a highly prevalent and underdiagnosed condition that may affect the outcome of COPD.

3777. Outcomes of a Peri- and Postoperative Management Protocol for Non-TB Mycobacteria in Lung Transplant Recipients.

作者: Takashi Hirama.;Lianne G Singer.;Sarah K Brode.;Theodore K Marras.;Shahid Husain.
来源: Chest. 2020年158卷2期523-528页

3778. Effect of Intermittent or Continuous Feed on Muscle Wasting in Critical Illness: A Phase 2 Clinical Trial.

作者: Angela S McNelly.;Danielle E Bear.;Bronwen A Connolly.;Gill Arbane.;Laura Allum.;Azhar Tarbhai.;Jackie A Cooper.;Philip A Hopkins.;Matthew P Wise.;David Brealey.;Kieron Rooney.;Jason Cupitt.;Bryan Carr.;Kiran Koelfat.;Steven Olde Damink.;Philip J Atherton.;Nicholas Hart.;Hugh E Montgomery.;Zudin A Puthucheary.
来源: Chest. 2020年158卷1期183-194页
Acute skeletal muscle wasting in critical illness is associated with excess morbidity and mortality. Continuous feeding may suppress muscle protein synthesis as a result of the muscle-full effect, unlike intermittent feeding, which may ameliorate it.

3779. Emerging Concepts of the Pathophysiology and Adverse Outcomes of Restless Legs Syndrome.

作者: Sofía Romero-Peralta.;Irene Cano-Pumarega.;Diego García-Borreguero.
来源: Chest. 2020年158卷3期1218-1229页
Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a common neurological disorder affecting up to 5% to 10% of the population, but it remains an underdiagnosed condition. RLS/WED is characterized by uncomfortable sensations, mainly in the legs, which appear during inactivity and worsen in the evening or at night. The prevalence of RLS/WED and periodic leg movements (PLMs) is increased in patients with sleep-disordered breathing, particularly in those with OSA, the most common sleep disorder encountered in sleep centers. New advances in the pathophysiology of RLS/WED have shown important implications for various genetic markers, neurotransmitter dysfunction, and iron deficiency. A practical approach to RLS/WED management includes an accurate diagnosis, the identification of reversible contributing factors, and the use of nonpharmacological therapies, including iron substitution (oral or IV) therapy. Many pharmacological agents are effective for the treatment of RLS/WED. Until recently, the first-line treatment of RLS/WED consisted of low-dose dopamine agonists (DA). However, given the fact that DAs cause high rates of augmentation of symptoms, international guidelines recommend that whenever possible the initial treatment of choice should be an α2δ ligand, and avoidance of dopaminergic agents unless absolutely necessary. If necessary, the lowest effective dose should be used for only the shortest possible time. The symptoms of RLS/WED can disrupt the quality of sleep as well as the quality of life. IV iron therapy may be considered in patients with refractory RLS. A better understanding of RLS/WED pathophysiology will allow patients to receive tailored therapy, resulting in an improved quality of life.

3780. Preliminary Findings on Control of Dispersion of Aerosols and Droplets During High-Velocity Nasal Insufflation Therapy Using a Simple Surgical Mask: Implications for the High-Flow Nasal Cannula.

作者: Scott Leonard.;Charles W Atwood.;Brian K Walsh.;Ronald J DeBellis.;George C Dungan.;Wayne Strasser.;Jessica S Whittle.
来源: Chest. 2020年158卷3期1046-1049页
共有 4060 条符合本次的查询结果, 用时 2.2916866 秒